Ernexa Therapeutics Inc. Share Price & Technical Analysis
ERNA · $12.14 (+1.08%)
Healthcare / Biotechnology
$12.14
+1.08%
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for …
Price chart
Seasonality
May has 3 positive and 2 negative years (last 5 years shown)
216% return in May, -4% avg return in past 3 year May month.
87% return in 2026, -74% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 4% | -76% | -31% | -27% | 216% | – | – | – | – | – | – | – | 87% |
| 25 | 19% | -19% | -40% | 11% | 10% | -47% | -6% | -22% | -24% | 71% | -28% | -6% | -81% |
| 24 | -11% | -9% | 43% | -28% | 7% | -4% | 3% | 3% | -41% | 6% | -60% | -36% | -127% |
| 23 | 48% | -21% | -12% | -15% | -30% | 2% | 23% | -12% | -13% | -34% | -31% | 82% | -14% |
| 22 | -36% | -16% | -12% | -49% | -36% | -26% | -6% | -18% | -40% | -36% | 2% | -2% | -276% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Downtrend · Strong
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$15.21M
P/E ratio
—
52W high
$101.3
52W low
$3.18
Volume
17,50,416
Beta
1.89
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Ernexa Therapeutics Inc. share price today?
- Ernexa Therapeutics Inc. (ERNA) last traded around $12.14 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ERNA have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ERNA. Download the app for real-time alerts.
- How can I analyze Ernexa Therapeutics Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.